Race Alone Should Not Be Used To Allocate Scarce COVID-19 Treatments

In hospitals and health care systems, life and death decisions are being made about who should get scarce antiviral medications from Pfizer and Merck and monoclonal antibodies from AstraZeneca and Vir/GSK. These medicines can keep people out of the hospital and save lives.

Read the op-ed here.